Abstract：Objective To explore the clinical effect of Mosapride Citrate combined with Aluminum Phosphate in the treatment of bile reflux gastritis.Methods A total of 86 cases of bile reflux gastritis treated in our hospital from January 14,2017 to January 20,2018 were selected as the subjects and divided into the control group (43 cases)and the observation group(43 cases)according to the random number method.The control group was treated with PPI combined with Mosapride Citrate,and the observation group was given the PPI and Mosapride Citrate combined with Aluminum Phosphate.The clinical total effective rate and clinical symptom score(anti acid,nausea,abdominal distention,heartburn,upper abdominal pain)and the incidence of adverse reactions(constipation,dry mouth,diarrhea)were compared between the two groups.Results The total effective rate of the observation group after treatment was 97.67%(42/43),which was higher than that of the control group of 72.09% (31/43),and the difference was statistically significant(P＜0.05).The clinical scores of the observation group(sour regurgitation of[0.56±0.12]points,nausea of[0.33±0.12]points,abdominal distension of[0.58±0.15]points,heartburn of[0.63±0.20]points and epigastric pain of[0.52±0.10]points)were lower than those in the control group(sour regurgitation of[1.63±0.36]points,nausea of[1.36±0.26]points,abdominal distention of[1.65±0.40]points,heartburn of[2.36±0.78]points and epigastric pain of[1.98±0.52]points),the differences were statistically significant(P＜0.05).The incidence of adverse reactions after treatment in the observation group was 2.33%(1/43),which was lower than that in the control group of 18.60%(8/43),and the difference was statistically significant(P＜0.05).Conclusion The combination of Mosapride Citrate and Aluminum Phosphate is of high clinical value in the treatment of bile reflux gastritis.It can reduce the incidence of adverse reactions on the basis of relieving clinical symptoms.It is worth applying and popularizing.
京公网安备 11010502046607号